Engag\u00e9 \u00e0 am\u00e9liorer les r\u00e9sultats
\n<\/span> en oncologie<\/h1>\n<\/div><\/div><\/div><\/div><\/div>\u00c0 propos de nous<\/p>\n<\/div><\/div><\/div>
Leapfrog Bio is an emerging oncology therapeutics company leveraging our Precision PGx Platform to identify and develop novel targeted therapeutics.\u00a0 Our approach utilizes synthetic lethality and pharmacogenomic screening to reveal treatment options for patients suffering from cancer due to \u201closs of function\u201d mutations.\u00a0 We are passionate and aligned with our team, board and investors to achieve this important goal.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
<\/div>Direction<\/h2>\n<\/div><\/div><\/div><\/div><\/div>![](\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/10\/G_Vontz-1.jpg\")
Baccalaur\u00e9at en chimie, University of Florida \u2022 MBA, UC Berkeley Haas School of Business \u2022 Merck \u2022 Genentech \u2022 Connectics Corporation \u2022 Topica Pharmaceuticals \u2022 BlackThorn Therapeutics<\/p><\/div><\/div><\/a><\/span><\/div>
Greg Vontz<\/div>\nChef de la direction<\/div>\n<\/div><\/a><\/div><\/div><\/div><\/div><\/div>![](\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/10\/T_Babak-2.jpg\")
Doctorat en g\u00e9n\u00e9tique mol\u00e9culaire, University of Toronto \u2022 Professeur adjoint (biologie), Queen\u2019s University \u2022 Stanford University \u2022 Celgene \u2022 Merck \u2022 Bristol-Myers Squibb<\/p><\/div><\/div><\/a><\/span><\/div>
Tomas Babak, PhD<\/div>\nFondateur et directeur scientifique (CSO)<\/div>\n<\/div><\/a><\/div><\/div><\/div><\/div><\/div>![](\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/10\/P_Heinecke-2.jpg\")
Princeton University, AB Politics; University of Chicago JD and MBA; Morgan Stanley & Company, Wilson Sonsini Goodrich & Rosati, Xalud Therapeutics, Aimmune Therapeutics, BioElectron Technology Corporation.<\/p><\/div><\/div><\/a><\/span><\/div>
Peter Heinecke<\/div>\nChef du d\u00e9veloppement des affaires et conseiller juridique principal (CBO, GC)<\/div>\n<\/div><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Conseil d\u2019administration<\/h2>\n<\/div><\/div><\/div><\/div><\/div>Greg Vontz<\/div>\nCEO and Director<\/div>\n<\/div><\/a><\/div><\/div><\/div><\/div><\/div>Tomas Babak, PhD<\/div>\nCSO and Director<\/div>\n<\/div><\/a><\/div><\/div><\/div><\/div><\/div>Mike Goguen<\/div>\nPr\u00e9sident du conseil d\u2019administration<\/div>\n<\/div>
\u00c0 propos de nous<\/p>\n<\/div><\/div><\/div>
Leapfrog Bio is an emerging oncology therapeutics company leveraging our Precision PGx Platform to identify and develop novel targeted therapeutics.\u00a0 Our approach utilizes synthetic lethality and pharmacogenomic screening to reveal treatment options for patients suffering from cancer due to \u201closs of function\u201d mutations.\u00a0 We are passionate and aligned with our team, board and investors to achieve this important goal.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
Direction<\/h2>\n<\/div><\/div><\/div><\/div><\/div>Baccalaur\u00e9at en chimie, University of Florida \u2022 MBA, UC Berkeley Haas School of Business \u2022 Merck \u2022 Genentech \u2022 Connectics Corporation \u2022 Topica Pharmaceuticals \u2022 BlackThorn Therapeutics<\/p><\/div><\/div><\/a><\/span><\/div>
Greg Vontz<\/div>\nChef de la direction<\/div>\n<\/div><\/a><\/div><\/div><\/div><\/div><\/div>Doctorat en g\u00e9n\u00e9tique mol\u00e9culaire, University of Toronto \u2022 Professeur adjoint (biologie), Queen\u2019s University \u2022 Stanford University \u2022 Celgene \u2022 Merck \u2022 Bristol-Myers Squibb<\/p><\/div><\/div><\/a><\/span><\/div>
Tomas Babak, PhD<\/div>\nFondateur et directeur scientifique (CSO)<\/div>\n<\/div><\/a><\/div><\/div><\/div><\/div><\/div>Princeton University, AB Politics; University of Chicago JD and MBA; Morgan Stanley & Company, Wilson Sonsini Goodrich & Rosati, Xalud Therapeutics, Aimmune Therapeutics, BioElectron Technology Corporation.<\/p><\/div><\/div><\/a><\/span><\/div>
Peter Heinecke<\/div>\nChef du d\u00e9veloppement des affaires et conseiller juridique principal (CBO, GC)<\/div>\n<\/div><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Conseil d\u2019administration<\/h2>\n<\/div><\/div><\/div><\/div><\/div>Greg Vontz<\/div>\nCEO and Director<\/div>\n<\/div><\/a><\/div><\/div><\/div><\/div><\/div>Tomas Babak, PhD<\/div>\nCSO and Director<\/div>\n<\/div><\/a><\/div><\/div><\/div><\/div><\/div>Mike Goguen<\/div>\nPr\u00e9sident du conseil d\u2019administration<\/div>\n<\/div>
Baccalaur\u00e9at en chimie, University of Florida \u2022 MBA, UC Berkeley Haas School of Business \u2022 Merck \u2022 Genentech \u2022 Connectics Corporation \u2022 Topica Pharmaceuticals \u2022 BlackThorn Therapeutics<\/p><\/div><\/div><\/a><\/span><\/div>
Doctorat en g\u00e9n\u00e9tique mol\u00e9culaire, University of Toronto \u2022 Professeur adjoint (biologie), Queen\u2019s University \u2022 Stanford University \u2022 Celgene \u2022 Merck \u2022 Bristol-Myers Squibb<\/p><\/div><\/div><\/a><\/span><\/div>
Princeton University, AB Politics; University of Chicago JD and MBA; Morgan Stanley & Company, Wilson Sonsini Goodrich & Rosati, Xalud Therapeutics, Aimmune Therapeutics, BioElectron Technology Corporation.<\/p><\/div><\/div><\/a><\/span><\/div>
![](\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/two-bear-capital.png\")
<\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/p>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-41","page","type-page","status-publish","hentry"],"yoast_head":"\n